Working groups

Working Group XI: Patient Involvement in Development and Safe Use of Medicines

WG Member area: to access the Working Group documents please click one of the links below:


Working Group XI – Patient Involvement

Participants at the fourth meeting of the Working Group, Basel, 16-17 October 2019


The importance of patient involvement throughout the life cycle of pharmaceutical products, from their development to their use on the market has increasingly been recognized. Patients are now invited to state their perspectives and preferences on new needed medicines, to provide input to regulatory benefit-risk assessments through public hearings and consultations, and to submit adverse reaction reports to pharmacovigilance systems using new technologies such as mobile apps or social media.

Previous CIOMS guidelines have recognized the role of patients as key stakeholders in the safe and effective use of medicines, and some input from patients themselves was obtained for the first time by the CIOMS Working Group (WG) IX when formulating its guidance on Practical Approaches for Risk Minimisation of Medicinal Products.

Working Group objectives

The CIOMS Working Group XI on patient involvement in the development and safe use of medicines was launched in April 2018. It includes participants from patient organizations, industry, regulators, academia and the World Medical Association. These experts are working together to formulate pragmatic Points to Consider in patient involvement. The guidance will provide a comprehensive overview of present knowledge and existing initiatives, and will address a wide range of the remaining challenges and practice gaps. The optimal consideration of patient perspectives will support the safe and effective use of medicines, thereby helping to improve the health of individuals and the public.


  • 1st meeting held on  19-20 April 2018, Geneva, Switzerland (minutes)
  • 2nd meeting held on 23–24 October 2018, Berlin, Germany (minutes)
  • Open meeting on patient involvement in development and safe use of medicines,
    30 April 2019
    (report, with links to presentations)
  • 3rd meeting held on 1-2 May 2019 in Geneva, Switzerland (minutes)
  • 4th meeting held on 16-17 October 2019 in Basel, Switzerland (minutes to follow)

CIOMS Working Groups usually take 2-4 years to finalize their guidance and recommendations. Most groups hold two in-person meetings per year, with telework in between. The groups make use of collaborative efforts and capitalize on existing initiatives in order to provide output that is as comprehensive as possible, does not duplicate other efforts and has added value.


Upcoming Meetings

13 - 14 May 2020

Tallinn, Estonia

3rd meeting of MedDRA Labelling Groupings Working Group

29 - 30 April 2020

Peapack, New Jersey, USA

2nd meeting of Benefit-Risk Balance for Medicinal Products WG

22 - 23 April 2020

Geneva, Switzerland

6th meeting of Clinical Research in Resource-Limited Settings Working Group

01 - 02 April 2020

Utrecht, Netherlands

5th Meeting Working Group XI Patient Involvement in Developmnt/Safe Use Medicines

18 December 2019

Geneva, Switzerland

CIOMS 86th Executive Committee Meeting and XXIII General Assembly

Recent Meetings